3 results
The purpose of the study is to investigate how quickly and to what extent UCB0599 and UCB2713 are absorbed, distributed, metabolized (broken down) and excreted from the body (this is called pharmacokinetics). Since UCB0599 and UCB2713 will be…
The objective of the current study is to investigate the possible effects on driving ability of a new anti-depressant (10 mg Lu AA21004) after 1 day of dosing and after 15 days of dosing. These effects will be compared to those of mirtazapine (30 mg…
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…